MMP inhibition modulates TNF-α transgenic mouse phenotype early in the development of heart failure

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 282, Issue 3 51-3, 2002, Pages

  Li, Yun You ^a   Kadokami, Toshiaki ^a   Wang, Ping ^a   McTiernan, Charles F ^a   Feldman, Arthur M ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Collagen; Extracellular matrix; Metalloendopeptidases; Ventricular remodeling

Indexed keywords

BATIMASTAT; COLLAGEN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; EXTRACELLULAR MATRIX; GENE OVEREXPRESSION; HEART FAILURE; HEART HYPERTROPHY; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DENATURATION; PROTEIN EXPRESSION; SURVIVAL; TRANSGENIC MOUSE;

EID: 0036084756     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00233.2001     Document Type: Article

References (41)

1. Fibrogenesis. II. Metalloproteinases and their inhibitors in liver fibrosis
2. Holding it all together: Organization and function(s) of the extracellular matrix of the heart
3. Synthetic inhibitors of matrix metalloproteinases
4. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor
5. Myocardial matrix metalloproteinase activity and abundance with congestive heart failure
6. Matrix metalloproteinases and cardiovascular disease
7. Role of extracellular matrix in dilated cardiomyopathy
8. Collagen degradation in the heart
9. Ventricular remodeling in heart failure: The role of myocardial collagen
10. Sex-related survival differences in murine cardiomyopathy are associated with differences in TNF-receptor expression
11. Can trasmitral Doppler E-waves differentiate hypertensive hearts from normal?
12. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-α
13. A serine elastase inhibitor reduces inflammation and fibrosis and preserves cardiac function after experimentally-induced murine myocarditis
14. MMP/TIMP expression in spontaneously hypertensive heart failure rats: The effect of ACE- and MMP-inhibition
15. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart
16. Downregulation of matrix metalloproteinases and reduction in collagen damage in the failing human heart after support with left ventricular assist devices
17. Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy
18. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling
19. Proinflammatory cytokines regulate tissue inhibitors of metalloproteinases and disintegrin metalloproteinase in cardiac cells
20. Diastolic dysfunction as a cause of heart failure
21. Dynamic regulation of the extracellular matrix after mechanical unloading of the failing human heart: Recovering the missing link in left ventricular remodeling
22. 2+ in rat experimental wounds
23. Angiotensin-converting enzyme and matrix metalloproteinase inhibition with developing heart failure: Comparative effects on left ventricular function and geometry
24. Specific hybridization probes for mouse type I, II, III and IX collagen mRNAs
25. Preparation and characterization of the different types of collagen
26. Alteration of collagen phenotypes in ischemic cardiomyopathy
27. The determination of collagen and elastin in tissues
28. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice
29. New drugs on the horizon: Matrix metalloproteinase inhibitors
30. Matrix metalloproteinase inhibition during the development of congestive heart failure: Effects on left ventricular dimensions and function
31. Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: Relation to ventricular and myocyte function
32. Determination of hydroxyproline
33. Growth factors in the extracellular matrix
34. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy
35. Matrix metalloproteinase activity expression in infarcted, noninfarcted and dilated cardiomyopathic human hearts
36. Direct extraction and estimation of collagenase(s) activity by zymography in microquantities of rat myocardium and uterus
37. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice
38. Matrix metalloproteinase inhibitors
39. Reduction in myocardial collagen cross-linking parallels left ventricular dilatation in rat models of systolic chamber dysfunction
40. Matrix metalloproteinase (MMP) inhibition selectively decreases type II MMP activity in a murine model of pancreatic cancer